Results 191 to 200 of about 9,635 (207)

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

New England Journal of Medicine, 2018
Lucy Burr, Marcus A Mall, Edward F Mckone   +2 more
exaly  

Ivacaftor/lumacaftor

Reactions Weekly, 2018
  +4 more sources

Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis

American Journal of Respiratory and Critical Care Medicine, 2014
Sonya L Heltshe, Scott H Donaldson, Scott D Sagel   +2 more
exaly  

Ivacaftor

Reactions Weekly, 2015
openaire   +1 more source

Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data

American Journal of Respiratory and Critical Care Medicine, 2015
Gregory S Sawicki, Edward F Mckone, David J Pasta   +2 more
exaly  

Ivacaftor/lumacaftor/Ivacaftor/tezacaftor

Reactions Weekly
openaire   +1 more source

Ivacaftor withdrawal

Reactions Weekly, 2022
openaire   +1 more source

Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy

American Journal of Respiratory and Critical Care Medicine, 2019
Andrea Kelly, Saba Sheikh, Darko Stefanovski   +2 more
exaly  

Elexacaftor/Ivacaftor/tezacaftor/Ivacaftor

Reactions Weekly
openaire   +1 more source

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial

Lancet Respiratory Medicine,the, 2015
Richard Moss, Patrick A Flume, Susanna A Mccolley   +2 more
exaly